$121.58 -0.8 -0.7%
Last Trade - 25/02/21
| Market Cap | £153.70bn |
| Enterprise Value | £162.14bn |
| Revenue | £24.70bn |
| Position in Universe | 42nd / 6718 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 20,405 | 20,853 | 27,390 | 30,578 | 31,904 | 34,608 | 38,623 | 39,676 | +11.1% | ||
| +47.5 | -58.9 | +60.9 | +28.2 | +40.3 | +17.7 | +76.3 | +5.20 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Company focuses on cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicine. It offers products, including FreeStyle, PediaSure, Pedialyte, Similac, EleCare, ZonePerfect, Juven, Ensure and Glucerna. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. The cardiovascular's products include Portico, MitraClip, Dilatation Catheter, among others. The diagnostics products include IntelliFISH, Vysis ALK, STARLIMS, PathVysion, AlinIQ, among others.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | March 6, 1900 |
| Public Since | March 1, 1937 |
| No. of Shareholders: | 37,450 |
| No. of Employees: | 109,000 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Global 100, S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | New York Stock Exchange |
| Shares in Issue | 1,771,529,358 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 100 Abbott Park Rd, ABBOTT PARK, 60064-3500, United States |
| Web | https://www.abbott.com |
| Phone | +1 224 6676100 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 25/02/21, shares in Abbott Laboratories are trading at $121.58, giving the company a market capitalisation of £153.70bn. This share price information is delayed by 15 minutes.
Shares in Abbott Laboratories are currently trading at $121.58 and the price has moved by 49.43% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abbott Laboratories price has moved by 13.4% over the past year.
Of the analysts with advisory recommendations for Abbott Laboratories, there are there are currently 8 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Abbott Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Abbott Laboratories is scheduled to issue upcoming financial results on the following dates:
The Abbott Laboratories dividend yield is 1.18% based on the trailing twelve month period.
Last year, Abbott Laboratories paid a total dividend of 1.44, and it currently has a trailing dividend yield of 1.18%. Looking ahead, shares in Abbott Laboratories are due to go ex-dividend on 2021-04-14 and the next dividend pay date is 2021-05-17.
Abbott Laboratories are due to go ex-dividend on 2021-04-14 and the next dividend pay date is 2021-05-17. The historic dividend yield on Abbott Laboratories shares is currently 1.18%.
To buy shares in Abbott Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Abbott Laboratories are currently trading at $121.58, giving the company a market capitalisation of £153.70bn.
Here are the trading details for Abbott Laboratories:
Based on an overall assessment of its quality, value and momentum, Abbott Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Abbott Laboratories are currently priced at $121.58. At that level they are trading at 1.54% premium to the analyst consensus target price of 0.00.
Analysts covering Abbott Laboratories currently have a consensus Earnings Per Share (EPS) forecast of 4.402 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbott Laboratories. Over the past six months, the relative strength of its shares against the market has been -2.15%. At the current price of $121.58, shares in Abbott Laboratories are trading at 15.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abbott Laboratories PE ratio based on its reported earnings over the past 12 months is 48.7. The shares are currently trading at $121.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abbott Laboratories's management team is headed by:
Here are the top five shareholders of Abbott Laboratories based on the size of their shareholding:
